Citations

Clear

9383 citation(s) found for "Thomas, PS".

Clinical outcomes of anatomical versus reverse total shoulder arthroplasty in patients with primary osteoarthritis, an intact rotator cuff, and limited forward elevation
Trammell, Amy P. , Hao, Kévin A. , Hones, Keegan M. , Wright, Thomas W. , Vasilopoulos, Terrie , Wright, Thomas W , Hao, Kevin A , Hones, Keegan M , Wright, Jonathan O. , Schoch, Bradley S. , King, Joseph J.

Mayo Clinic

The Bone & Joint Journal | November 30, 2023 | Volume: 105-B | Issue: 12 | Pages: 1303-1313

10.1302/0301-620x.105b12.bjj-2023-0496.r2 | PMID 38037676 Get It

Aims Both anatomical and reverse total shoulder arthroplasty (aTSA and rTSA) provide functional improvements. A reported benefit of aTSA is better range of motion (ROM). However, it is not clear which procedure provides better outcomes in patients with limited foward elevation (FE). The aim of this study was to compare the outcome of aTSA and rTSA in patients with glenohumeral osteoarthritis (OA), an intact rotator cuff, and limited FE. Methods This was a retrospective review of a single institution’s prospectively collected shoulder arthroplasty database for TSAs undertaken between 2007 and 2020. A total of 344 aTSAs and 163 rTSAs, which were performed in patients with OA and an intact rotator cuff with a minimum follow-up of two years, were included. Using the definition of preoperative stiffness as passive FE ≤ 105°, three cohorts were matched 1:1 by age, sex, and follow-up: stiff aTSAs (85) to non-stiff aTSAs (85); stiff rTSAs (74) to non-stiff rTSAs (74); and stiff rTSAs (64) to stiff aTSAs (64). We the compared ROMs, outcome scores, and complication and revision rates. Results Compared with non-stiff aTSAs, stiff aTSAs had poorer passive FE and active external rotation (ER), whereas there were no significant postoperative differences between stiff rTSAs and non-stiff rTSAs. There were no significant differences in preoperative function when comparing stiff aTSAs with stiff rTSAs. However, stiff rTSAs had significantly greater postoperative active and passive FE (p = 0.001 and 0.004, respectively), and active abduction (p = 0.001) compared with stiff aTSAs. The outcome scores were significantly more favourable in stiff rTSAs for the Shoulder Pain and Disability Index, Simple Shoulder Test, American Shoulder and Elbow Surgeons score, University of California, Los Angeles score, and the Constant score, compared with stiff aTSAs. When comparing the proportion of stiff aTSAs versus stiff rTSAs that exceeded the minimal clinically important difference and substantial clinical benefit, stiff rTSAs achieved both at greater rates for all measurements except active ER. The complication rate did not significantly differ between stiff aTSAs and stiff rTSAs, but there was a significantly higher rate of revision surgery in stiff aTSAs (p = 0.007). Conclusion Postoperative overhead ROM, outcome scores, and rates of revision surgery favour the use of a rTSA rather than aTSA in patients with glenohumeral OA, an intact rotator cuff and limited FE, with similar rotational ROM in these two groups. Cite this article: Bone Joint J 2023;105-B(12):1303–1313.
Assessment of Improved Quality via the Adoption of Microbiology Automation
Lau, J. , Rice, Francine J., Lau, J, Larsen, J, Grys, Thomas E. , Rice, F, Graf, Erin H.

Mayo Clinic

American Journal of Clinical Pathology | November 29, 2023 | Volume: 160 | Issue: Supplement_1 | Pages: S86-S86

10.1093/ajcp/aqad150.191 Get It

Abstract Introduction/Objective Our laboratory implemented a full COPAN WASPLab microbiology automation line in March of 2023. Prior to this implementation, our laboratory routinely observed potential bacterial contamination of sterile specimens, as well as culture plates in which the specimens were not struck out, due to a large number of new staff members and heavy workloads. Both of these quality issues directly impact patient care due to potential misleading or delayed results. We hypothesized that automation of the plating and incubation steps would reduce both of these quality issues significantly. Methods/Case Report Potential contamination and plates not struck were self-reported by technologists during pre- implementation (July 2022-Feb 2023) and post-implementation (Mar-Apr 2023) periods. Potential contamination was defined as one or two colonies of bacteria on a single agar plate, consistent with skin fora, from a normally sterile source specimen and reviewed by the Director for potential clinical correlation. Plates unstruck in the post- implementation period continued to include those manually set up. A 2 two proportion z-test was performed to compare pre and post implementation data. Results (if a Case Study enter NA) A total of 3,055 and 1,750 sterile source cultures were analyzed in the pre- and post-implementation periods, respectively. Of these, 109 versus 8 were designated as potential contamination, respectively, resulting in a significant reduction (Z stat 6.7, p<0.0001). For the plate streaking portion, 22,814 and 7,211 cultures were analyzed in the pre- and post-implementation periods, respectively. Of these, 21 versus 3 plates were not struck, respectively, resulting in a greater than 2-fold reduction per culture, but did not meet significance. Conclusion Implementation of microbiology automation significantly reduced skin flora contamination of sterile source cultures. Proportions of unstruck plates were also reduced, although these did not meet significance, likely due to the low numbers.
Sustained Culture of Safety After Select Agent Exposure
Larsen, Jeremy T. , Lau, Jocelyn , Karsten, Jaap, Wrobel, R. , Francis, D. P., Lau, J, Grys, Thomas E. , Graf, Erin H. , Wrobel, R

Mayo Clinic

American Journal of Clinical Pathology | November 29, 2023 | Volume: 160 | Issue: Supplement_1 | Pages: S88-S88

10.1093/ajcp/aqad150.195 Get It

Abstract Introduction/Objective In January of 2021 our laboratory experienced the occupational exposure of 3 technologists to the select agent Burkholderia pseudomallei due to improper recognition and manipulation outside a biosafety cabinet. Subsequently, an interactive computer module was created to train technologists on timely recognition, followed by a “fake” patient test to evaluate comprehension. In that initial period, 100% compliance and successful recognition was demonstrated. To evaluate sustained compliance and recognition, another wave of evaluation was performed Jan- Dec 2022. Methods/Case Report During the study period several new staff members were hired and demonstrated compliance with completing the computer module. Clinical isolates suspicious for a select agent were reported to the Medical Director on rounds daily and reviewed for potential exposure, which was defined as manipulation of the suspicious isolate outside of the biosafety cabinet. Additional challenge “fake” patients were circulated. Results (if a Case Study enter NA) During the study period, 16 isolates were deemed suspicious for select agents based on macroscopic and microscopic morphology and biochemical reactions. Of these, 0 resulted in laboratory exposures. Of the challenge isolates, 1 resulted in a near-miss potential for exposure due to the lack of recognition of macroscopic characteristics. Conclusion The use of an interactive computer module focused around timely recognition and safe handling of potential select agents resulted in sustained laboratory safety and avoidance of potential occupational exposures.
Efficacy and Adherence Rates of a Novel Community‐Informed Virtual World‐Based Cardiac Rehabilitation Program: Protocol for the Destination Cardiac Rehab Randomized Controlled Trial
Brewer, LaPrincess C. , Abraham, Helayna , Clark, Donald , Echols, Melvin , Hall, Michael E. , Hodgman, Karen, Kaihoi, Brian, Kopecky, Stephen L. , Krogman, Ashton , Leth, Shawn , Malik, Shaista , Scales, Robert , Schulte, Phillip J. , Shultz, Adam M. , Wong, Nathan D. , Olson, Thomas P. , Hall, Michael , Kopecky, Stephen L , Marsteller, Jill , Mathews, Lena , Scales, Robert , Schulte, Phillip , Shultz, Adam , Thomas, Randal , Wong, Nathan , Olson, Thomas , Brewer, LaPrincess C , Taylor, Bryan J. , Thomas, Randal J.

Mayo Clinic

Journal of the American Heart Association | November 28, 2023 | Volume: 12 | Issue: 23 | Pages: No page available

10.1161/jaha.123.030883 | PMID 38014699 Get It

Background Innovative restructuring of cardiac rehabilitation (CR) delivery remains critical to reduce barriers and improve access to diverse populations. Destination Cardiac Rehab is a novel virtual world technology‐based CR program delivered through the virtual world platform, Second Life, which previously demonstrated high acceptability as an extension of traditional center‐based CR. This study aims to evaluate efficacy and adherence of the virtual world–based CR program compared with center‐based CR within a community‐informed, implementation science framework. Methods Using a noninferiority, hybrid type 1 effectiveness‐implementation, randomized controlled trial, 150 patients with an eligible cardiovascular event will be recruited from 6 geographically diverse CR centers across the United States. Participants will be randomized 1:1 to either the 12‐week Destination Cardiac Rehab or the center‐based CR control groups. The primary efficacy outcome is a composite cardiovascular health score based on the American Heart Association Life's Essential 8 at 3 and 6 months. Adherence outcomes include CR session attendance and participation in exercise sessions. A diverse patient/caregiver/stakeholder advisory board was assembled to guide recruitment, implementation, and dissemination plans and to contextualize study findings. The institutional review board–approved randomized controlled trial will enroll and randomize patients to the intervention (or control group) in 3 consecutive waves/year over 3 years. The results will be published at data collection and analyses completion. Conclusions The Destination Cardiac Rehab randomized controlled trial tests an innovative and potentially scalable model to enhance CR participation and advance health equity. Our findings will inform the use of effective virtual CR programs to expand equitable access to diverse patient populations. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05897710.
Genotype-Phenotype Taxonomy of Hypertrophic Cardiomyopathy
Curran, Lara , Marvao, Antonio de , Inglese, Paolo , McGurk, Kathryn A. , Schiratti, Pierre-Raphaël , Clement, Adam , Li, Surui, Pua, Chee Jian, Shah, Mit , Jafari, Mina , Buchan, Rachel , Jurgens, Sean J. , Baksi, A. John , Pantazis, Antonios , Halliday, Brian P. , Pennell, Dudley J. , Prasad, Sanjay, Ware, James S. , de Marvao, Antonio , Pua, Chee Jian , Jafari, Mina , Theotokis, Pantazis , Jurgens, Sean J , Raphael, Claire , Pennell, Dudley J , Bai, Wenjia , Bezzina, Connie R , Watkins, Hugh , Cook, Stuart A. , Prasad, Sanjay K , Buchan, Rachel , Ware, James S , Zheng, Sean Lee , Theotokis, Pantazis , Raphael, Claire E. , Chin, Calvin , Tadros, Rafik , Bezzina, Connie R. , Watkins, Hugh , O’Regan, Declan P.

Mayo Clinic

Circulation: Genomic and Precision Medicine | November 28, 2023 | Volume: 16 | Issue: 6 | Pages: No page available

10.1161/circgen.123.004200 | PMID 38014537 Get It

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an important cause of sudden cardiac death associated with heterogeneous phenotypes, but there is no systematic framework for classifying morphology or assessing associated risks. Here, we quantitatively survey genotype-phenotype associations in HCM to derive a data-driven taxonomy of disease expression. METHODS: We enrolled 436 patients with HCM (median age, 60 years; 28.8% women) with clinical, genetic, and imaging data. An independent cohort of 60 patients with HCM from Singapore (median age, 59 years; 11% women) and a reference population from the UK Biobank (n=16 691; mean age, 55 years; 52.5% women) were also recruited. We used machine learning to analyze the 3-dimensional structure of the left ventricle from cardiac magnetic resonance imaging and build a tree-based classification of HCM phenotypes. Genotype and mortality risk distributions were projected on the tree. RESULTS: Carriers of pathogenic or likely pathogenic variants for HCM had lower left ventricular mass, but greater basal septal hypertrophy, with reduced life span (mean follow-up, 9.9 years) compared with genotype negative individuals (hazard ratio, 2.66 [95% CI, 1.42–4.96]; P <0.002). Four main phenotypic branches were identified using unsupervised learning of 3-dimensional shape: (1) nonsarcomeric hypertrophy with coexisting hypertension; (2) diffuse and basal asymmetrical hypertrophy associated with outflow tract obstruction; (3) isolated basal hypertrophy; and (4) milder nonobstructive hypertrophy enriched for familial sarcomeric HCM (odds ratio for pathogenic or likely pathogenic variants, 2.18 [95% CI, 1.93–2.28]; P =0.0001). Polygenic risk for HCM was also associated with different patterns and degrees of disease expression. The model was generalizable to an independent cohort (trustworthiness, M 1 : 0.86–0.88). CONCLUSIONS: We report a data-driven taxonomy of HCM for identifying groups of patients with similar morphology while preserving a continuum of disease severity, genetic risk, and outcomes. This approach will be of value in understanding the causes and consequences of disease diversity.
Standardization of Videorecorded Speech Samples for Children with Cleft Palate: Methods to Facilitate High-Quality Speech Outcomes Data Collection
Baylis, Adriane L. , Cummings, Caitlin E., Lien, Kari M. , Sitzman, Thomas J. , Kirschner, Richard E. , Chapman, Kathy , Chapman, Kathy L , Sitzman, Thomas J , Cummings, Caitlin A.

Mayo Clinic

The Cleft Palate Craniofacial Journal | November 28, 2023 | Volume: 61 | Issue: 12 | Pages: 2090-2096

10.1177/10556656231217645 | PMID 38013453 Get It

Background Collection of high-quality videorecorded speech samples is essential for speech outcomes research. Solution Cleft palate team SLPs were trained to collect standard videorecorded speech samples in the clinic setting across 20 sites in North America. Standard training and equipment was provided. What We Did That is New Quality management procedures were developed and utilized to verify video quality and protocol adherence. Over 97% of speech samples collected by trained SLPs met defined quality standards.
Climate Change and Cancer Care: A Policy Statement From ASCO
Bernicker, Eric , Averbuch, Steve D. , Edge, Stephen B. , Kamboj, Jasmine , Khuri, Fadlo R. , Pierce, Jennifer Young , Schiller, Joan H. , Sirohi, Bhawna , Thomas, Alexandra , Moushey, Allyn , Phillips, Jonathan , Hendricks, Carolyn B., Edge, Stephen , Schiller, Joan , Sirohi, Bhawna

Mayo Clinic

JCO Oncology Practice | November 27, 2023 | Volume: 20 | Issue: 2 | Pages: 178-186

10.1200/op.23.00637 | PMID 38011607 Get It

COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
Habtehyimer, Feben , Zhu, Xianming , Redd, Andrew D. , Patel, Eshan U. , Laeyendecker, Oliver , Gniadek, Thomas J. , Fernández, Reinaldo E. , Baker, Owen R. , Ram, Malathi , Cachay, Edward R. , Fukuta, Yuriko , Gerber, Jonathan M. , Heath, Sonya L. , Huamán, Moisés A. , Blair, Janis E. , Cruser, Daniel, Forthal, Donald N. , Hammitt, Laura L. , Patel, Bela , Abinante, Matthew, Oei, Kevin , Cluzet, Valerie , Cordisco, Marie Elena , Greenblatt, Benjamin, Rausch, William, Shade, David , Gawad, Amy L., Bloch, Evan M. , Patel, Eshan U , Laeyendecker, Oliver , Forthal, Donald N , Sutcliffe, Catherine G , Klein, Sabra L , Pekosz, Andrew , Casadevall, Arturo , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Zhu, Xianming , Gebo, Kelly A , Abraham, Alison G. , Currier, Judith S. , Meisenberg, Barry R. , Levine, Adam C , Shenoy, Aarthi , Anjan, Shweta , Kassaye, Seble , Mosnaim, Giselle S , Paxton, James H , Raval, Jay S. , Shoham, Shmuel , Casadevall, Arturo , Hanley, Daniel F. , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

Microbiology Spectrum | November 27, 2023 | Volume: 12 | Issue: 1 | Pages: No page available

10.1128/spectrum.03286-23 | PMID 38009954 Get It

ABSTRACT Early COVID-19 convalescent plasma (CCP) transfusion to outpatients with COVID-19 decreases progression to hospitalization, but the mechanism of how CCP reduces severity is unknown. Among 882 COVID-19 participants transfused with CCP or control plasma in a randomized controlled trial, 21 cytokines and chemokines were measured using electrochemiluminescence assays. Wilcoxon rank sum tests were used to evaluate the difference between early (transfused within 5 days of symptom onset) CCP vs early control plasma and late (transfused 6–9 days after symptom onset) CCP vs late control plasma at each visit. Linear mixed-effect models were used to assess the difference in the slope of cytokine change. Median cytokine and chemokine levels were similar between the early CCP and early control groups pre-transfusion. At the day 14 visit, only the median IL-6 ( P = 0.014) and IL-16 ( P = 0.036) levels were lower in the early CCP group compared to the early control group, but these differences were not statistically significant after correcting for multiple comparisons (requiring P < 0.0024). IL-6 levels decreased significantly faster in the early CCP group from screening to the day 14 visit compared to the early control group ( P < 0.001). No difference was observed in the slope of cytokine change from screening to day 90 between early CCP and early control groups. Late control and late CCP arms showed similar cytokine and chemokine levels through study follow-up. One mechanism by which early CCP transfusion reduces hospitalization may be by decreasing IL-6 levels, as the reduction is associated with better recovery from COVID-19. IMPORTANCE This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.
401. Risk of Post-COVID Conditions Correlates with IL-6 Plasma Levels and Is Reduced by Early Antibody Therapy
Fukuta, Yuriko , Heath, Sonya L. , Baksh, Sheriza , Habtehyimer, Feben , Shade, David , Ruff, Jessica E. , Ram, Malathi , Fernández, Reinaldo E. , Baker, Owen R. , Cachay, Edward R. , Gerber, Jonathan M. , Hammitt, Laura L. , Forthal, Donald N. , Patel, Bela, Gniadek, Thomas J. , Blair, Janis E. , Lane, Karen , McBee, Nichol , Gawad, Amy L., Das, Piyali, Bloch, Evan M. , Gebo, Kelly A , Zhu, Xianming , Abraham, Alison G. , Laeyendecker, Oliver , Patel, Eshan U. , Shoham, Shmuel , Currier, Judith S. , Meisenberg, Barry R. , Huamán, Moisés A. , Levine, Adam C , Mosnaim, Giselle S , Paxton, James H , Raval, Jay S. , Sutcliffe, Catherine G , Anjan, Shweta , Kassaye, Seble , Klein, Sabra L , Pekosz, Andrew , Hanley, Daniel F. , Casadevall, Arturo , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

Open Forum Infectious Diseases | November 27, 2023 | Volume: 10 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofad500.471 Get It

Abstract Background Post-COVID conditions (PCC) are common, and risk factors include older age and female sex. While high interleukin (IL)-6 and C-reactive protein are associated with more severe disease, it is unclear whether other cytokines are associated with PCC. This study was performed to identify factors associated with PCC development. Methods The Convalescent Plasma to Limit SARS-CoV-2 Associated Complications (CSSC-004) trial was a double-blind, multi-center, randomized, controlled trial comparing the use of COVID-19 convalescent plasma (CCP) to control plasma for the prevention of hospitalization among COVID-19 outpatients. Among 882 individuals participating in the trial with available biospecimens and symptom data, the association between early COVID-19 treatment, cytokine levels and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14 and day 90 using a multiplexed sandwich immuosassay. Presence of any PCC symptom was assessed at day 90. Associations between COVID-19 treatment, cytokine levels and PCC were examined using multivariate logistic regression models. Results Baseline characteristics were similar by trial treatment group (Figure 1). At day 90, 292 (33.1%) participants had PCC. The most common symptoms were fatigue (14.5%), anosmia (14.5%), and ageusia (10.0%). Levels of most cytokines decreased over time (Figure 2). Six pro-inflammatory cytokines especially IL-6 were elevated at baseline among those with PCC (Figure 3). In multivariable analysis, female sex (adjusted odds ratio [AOR]=2.70[1.93-3.81]), age 50 or greater (AOR=1.32[1.17-1.50]), and elevated baseline IL-6 (AOR=1.59[1.02-2.47]) were associated with development of PCC, whereas race, obesity, vaccine status and diabetes were not. Those who received early CCP treatment (&lt;5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC (AOR=0.60 [0.38-0.95]). Conclusion This study showed high prevalence of PCC symptoms at day 90, particularly among those with higher baseline levels of IL-6 or who did not receive early CCP treatment. The potential utility of IL-6 modulation as a therapeutic intervention among individuals as higher risk for PCC should be studied. Disclosures Kelly Gebo, MD, MPH, Pfizer: Advisor/Consultant|Spark HealthCare: Advisor/Consultant Sonya L. Heath, MD, Pfizer: Data Monitoring Committee/DSMB Shmuel Shoham, MD, adagio: Advisor/Consultant|Adamis: Advisor/Consultant|ansun: Grant/Research Support|Avir Pharma: Honoraria|cidara: Grant/Research Support|F2G: Grant/Research Support|Immunome: Advisor/Consultant|Karius: Honoraria|Scynexis: Advisor/Consultant|zeteo: Grant/Research Support Judith S. Currier, M.D., MSc, Merck and Company: Advisor/Consultant|Merck and Company: Honoraria Moises A. Huaman, MD, MSc, AN2 Therapeutics Inc: Grant/Research Support|Gilead Sciences Inc: Grant/Research Support|Insmed Inc: Grant/Research Support Jay S. Raval, MD, Sanofi Genzyme: Advisor/Consultant Arturo Casadevall, MD, PhD, Ortho Diagnostics: Speakers Bureau|Sabtherapeutics: Advisor/Consultant
142. When You Can't Call It Colonization, Consider Cutting It Out: Mitigating Panels of Unusual Size to Improve C. difficile Diagnostic Specificity
Grant, Leah , Huang, Angela , Siebeneck, Eric, Castro, J Mendoza, Seville, Maria Teresa , Speiser, Lisa , Ilges, Dan , Grys, Thomas E. , Graf, Erin H.

Mayo Clinic

Open Forum Infectious Diseases | November 27, 2023 | Volume: 10 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofad500.215 Get It

Abstract Background The BioFire® FilmArray® Gastrointestinal Pathogen Panel (GIPP) tests for 22 potential pathogens in stool, including Clostridioides difficile. C. difficile nucleic acid is detected via nested polymerase chain reaction (PCR) targeting toxin A (TcdA) and/or toxin B (TcdB) genes. While PCR-based diagnostic methods are highly sensitive, they lack specificity to differentiate colonization from C. difficile infection (CDI). Mayo Clinic Arizona (MCA) uses enzyme immunoassay (EIA) testing for toxin A/B and glutamate dehydrogenase antigens with reflex to PCR for discordance as the primary algorithm for diagnosing CDI; however, GIPP PCR testing circumvents this algorithm. When used in patients with low pretest probability for CDI, clinical false positives can lead to inappropriate diagnosis and treatment of colonization. GIPA Results in the Electronic Medical Record Pre-Intervention MCA Standalone C. difficile Testing Algorithm Abbreviations – EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; NAAT, nucleic acid amplification test Methods We convened a multidisciplinary quality improvement team to reduce the detection and treatment of C. difficile colonization secondary to GIPP test results. Surveys were sent to providers and nurses as part of a formal gap analysis and included questions around ordering patterns, knowledge of appropriate tests, and associated costs. Baseline data was compiled from GIPP orders in MCA from 1/1/2022-9/30/2022. Results There were 1978 GIPP orders for 1694 patients during the study period (∼7 GIPPs/day). Most orders (65%) originated from ambulatory settings. The most common positive target was C. difficile (355/723, 49%), which resulted in treatment for suspected CDI in 94.9% (337/355) of cases. Of the 49 providers who responded to the survey, 86% ordered the GIPP at least monthly. Testing for C. difficile was the 2nd most common reason for ordering the GIPP. Most providers underestimated the cost of the panel and were unfamiliar with the differences between the GIPP and EIA testing algorithm. Nurses sought clarification on stool samples suitable for GIPP testing. Following education and modifications to ordering in the electronic health record, the decision was made to remove the C. difficile target from the GIPP. Provider Understanding of C. difficile Testing Methods GIPA Results in the Electronic Medical Record Post-Intervention Conclusion Multiplex PCR panels are comprehensive but require careful implementation to facilitate diagnostic stewardship. Facilities with robust standalone C. difficile testing algorithms may consider removing the C. difficile target from the GIPP. Disclosures All Authors: No reported disclosures